MedTrace Logo

Type III Dysbetalipoproteinemia

NCT00214604 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-11-19

No results posted yet for this study

Summary

Evaluation of the efficacy of rosuvastatin 10mg, rosuvastatin 20mg and pravastatin 40mg in subjects with dysbetalipoproteinemia.

Conditions

  • Hyperlipoproteinemia Type III

Interventions

DRUG

Rosuvastatin

10mg

DRUG

rosuvastatin

20mg

DRUG

pravastatin

40mg

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Crestor Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • Norway
  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214604 on ClinicalTrials.gov